ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

ACS Plans 7 Hearings Around U.S. On cancer In The Disadvantaged

April 7, 1989

NCI Requests $5.69 Billion To Seize Opportunities In FY03.

January 11, 2002

Panel To Hear Centers’ Problems Again; Alabama, Mayo Impress Site visitors

March 18, 1977

NIDA Supports Phase III Trial of Anti-Tobacco Vaccine

November 6, 2009

In Brief: Landers Needles Pauling on Vitamin C Study Results; David Goldenberg Heads N.J. Center

October 21, 1983

Ovarian Cancer Screening Finds Cancers, But Also Many False Positives, Study Says

November 25, 2005